TrialInternational journal of hematology2024

A lower initial dose of bosutinib for patients with chronic myeloid leukemia patients resistant and/or intolerant to prior therapy: a single-arm, multicenter, phase 2 trial (BOGI trial).

Hiroshi Ureshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.